Dendreon Reschedules Third Quarter 2012 Results to November 2 Due to Hurricane Sandy

SEATTLE--(BUSINESS WIRE)--October 29, 2012–Dendreon Corporation (Nasdaq: DNDN) today announced that in light of Hurricane Sandy, the Company has rescheduled the release of its third quarter 2012 earnings results. Certain members of its senior management team and commercial operations are in the Company’s Bridgewater, New Jersey office, where the call was expected to originate. Dendreon will now be releasing its financial results on Friday, November 2, 2012, and will hold the related investor conference call the same day at 9:00 a.m. ET. The Company had previously planned to announce its third quarter 2012 earnings on October 30, 2012.

Conference Call Information

Dendreon will host a conference call on November 2, 2012 at 9:00 a.m. ET. To access the live call, dial 1-877-548-9590 (domestic) or [phone] (international); the conference ID number is 38408702. The call will also be audio webcast with supplemental information slides available from the Company's website at http://www.dendreon.com under the “Investor/Webcasts and Presentations” section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1- 800-585-8367 or [phone] for international callers; the conference ID number is 38408702. The replay will be available from 12:00 p.m. ET on Friday, November 2, until 11:59 p.m. ET on Friday, November 9. In addition, the webcast will be archived for on-demand listening for 90 days at www.dendreon.com and the supplemental information slides will be posted to the Company’s website.

About Dendreon

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy (ACI) product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon’s first product, PROVENGE® (sipuleucel-T), was approved by the U.S. Food and Drug Administration (FDA) in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington, and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.